Company intelligence / Profile preview

Akelos Inc.

New York, New York, United Statesakelosinc.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Akelos’ lead program is a first-in-class, non-opioid drug candidate for neuropathic and chronic pain. The company’s preclinical studies have shown promising results in calming hyperactive peripheral neurons by inhibiting HCN1 channels. The lead compound has achieved preclinical safety milestones and the company has received NIH funding to advance development toward clinical trials[4][5].

Therapeutic areas: Neurology
Modalities: Small molecules (non-opioid designer molecules targeting HCN1 ion channels)[1][2][3]
Industry: Biotech

Drug pipeline

2 assets

AKE-1018

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Weill Cornell Medicine (research collaboration)[3][5]

Beyond the preview

Go deeper on Akelos Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akelos Inc..

Explore the full profile